Takako Miyamae

Dr. Takako Miyamae

Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SYShumpei Yokota
Shumpei Yokota
TMTakako Miyamae
Takako Miyamae
YKYoshiyuki Kuroiwa
Yoshiyuki Kuroiwa
KNKusuki Nishioka
Kusuki Nishioka
The Novel Coronavirus Disease 2019 (COVID-19) has swept the world and caused a global pandemic. SARS-CoV-2 seems to have originated from bats as their reservoir hosts over time. Similar to SARS-CoV, this new virus also exerts its action on the human angiotensin-converting enzyme 2. This action causes infections in cells and establishes an infectious disease, COVID-19. Against this viral invasion, the human body starts to activate the innate immune system in producing and releasing proinflammatory cytokines such as IL-6, IL-1β, IL-8, TNF-α, and other chemokines, such as G-CSF, IP10 and MCPl, which all develop and increase the inflammatory response. In cases of COVID-19, excessive inflammatory responses occur, and exaggerated proinflammatory cytokines and chemokines are detected in the serum, resulting in cytokine release syndrome or cytokine storm. This causes coagulation abnormalities, excessive oxidation developments, mitochondrial permeability transition, vital organ damage, immune system failure and eventually progresses to disseminated intravascular coagulation and multiple organ failure. Additionally, the excessive inflammatory responses also cause mitochondrial dysfunction due to progressive and persistent stress. This damages cells and mitochondria, leaving products containing mitochondrial DNA and cell debris involved in the excessive chronic inflammation as damage-associated molecular patterns. Thus, the respiratory infection progressively leads to disseminated intravascular coagulation from acute respiratory distress syndrome, including vascular endothelial cell damage and coagulation-fibrinolysis system disorders. This condition causes central nervous system disorders, renal failure, liver failure and, finally, multiple organ failure. Regarding treatment for COVID-19, the following are progressive and multiple steps for mitigating the excessive inflammatory response and subsequent cytokine storm in patients. First, administering of favipiravir to suppress SARS-CoV-2 and nafamostat to inhibit ACE2 function should be considered. Second, anti-rheumatic drugs (monoclonal antibodies), which act on the leading cytokines (IL-1β, IL-6) and/or cytokine receptors such as tocilizumab, should be administered as well. Finally, melatonin may also have supportive effects for cytokine release syndrome, resulting in mitochondrial function improvement. This paper will further explore these subjects with reports mostly from China and Europe.

28 September 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
YKYohei Kirino
Yohei Kirino
AMAyaka Maeda
Ayaka Maeda
TATomoyuki Asano
Tomoyuki Asano
KMKiyoshi Migita
Kiyoshi Migita
YHYukiko Hidaka
Yukiko Hidaka
KTKensaku Takatsuki
Kensaku Takatsuki
We aimed to gather real-world clinical evidence of detailed disease activity, treatments, remission rates, and adverse events (AEs) associated with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a prospective study. Patients in Japan suspected of having VEXAS syndrome were enrolled in a registry study. A novel disease activity measure (VEXASCAF) assessing 11 symptoms associated with VEXAS syndrome was evaluated at enrolment and after 3 months. AEs, survival, CRP levels, and treatments were also recorded at enrolment and 3 months after enrolment. All exons of UBA1 were sequenced using a next-generation sequencer to determine the variant allele frequencies of pathogenic variants in the peripheral blood of all patients. Of the 55 registered patients, 30 patients were confirmed to have pathogenic variants of UBA1. All patients were male, with a median age of 73.5 years. VEXASCAF and CRP levels decreased significantly at 3 months post-enrolment, but the oral prednisolone dose did not change. Only two patients achieved complete remission according to FRENVEX at 3 months after enrolment. During the observation period of 6 months, 28 AEs were observed, including 3 deaths, 4 malignancies from two cases, 2 thromboses, and 13 infections (including 4 mycobacterial infections). Inflammation of the lung and cervical region (i.e. parotid and submandibular gland swelling, tonsillitis, cervical swelling, and pain) were the most common AEs. Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications—such as malignancy, thrombosis, and infection—occurred frequently within a short observation period.

7 March 2024 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
TMTakayuki Miyamoto
Takayuki Miyamoto
KIKazushi Izawa
Kazushi Izawa
SMSho Masui
Sho Masui
AYAtsue Yamazaki
Atsue Yamazaki
YYYuichi Yamasaki
Yuichi Yamasaki
TGthe Japan CAPS Working Group
the Japan CAPS Working Group


17 March 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TMTakako Miyamae
Takako Miyamae
TKTomohiro Kawabe
Tomohiro Kawabe
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder mainly characterised by increased risks of thrombosis and pregnancy morbidity and persistent positive test results for antiphospholipid antibodies (aPLs). The criteria for diagnosing juvenile APS have yet to be validated, while the Sydney classification criteria do not contain several non-thrombotic clinical manifestations associated with the presence of aPLs. As such, difficulties have been encountered in the diagnosis of patients who have no certain thrombotic occlusions. Moreover, extra-criteria manifestations (i.e., clinical manifestations not listed in the classification criteria), including neurologic manifestations (chorea, myelitis and migraine), haematologic manifestations (thrombocytopenia and haemolytic anaemia), livedo reticularis, nephropathy and valvular heart disease have been reported, which suggests that the clinical spectrum of aPL-related manifestations extends beyond that indicated in the classification criteria. Studies have demonstrated that more than 40% of children with aPLs demonstrated non-thrombotic aPL-related clinical manifestations alone. Moreover, our results showed that the pathogenesis of non-criteria manifestations is characterised by “APS vasculopathy”. The present review introduces the characteristics and findings of non-criteria manifestations observed in juvenile APS.

16 March 2017 in Modern Rheumatology Case Reports
Verified
Journal Article
Closed access
AHAki Hanaya
Aki Hanaya
TMTakako Miyamae
Takako Miyamae
TKTakayuki Kishi
Takayuki Kishi
MSMasumi Sahara
Masumi Sahara
YTYumi Tani
Yumi Tani
SNSatoru Nagata
Satoru Nagata
We report a 13-year-old Japanese boy with RASopathy (Noonan syndrome and Noonan-related syndromes) complicated by systemic lupus erythematosus (SLE). The diagnosis of RASopathy was made on the basis of stature and mental retardation, characteristic facial dysmorphia and sparse, thin hair. A heterozygous mutation in SHOC2 had been identified at the age of 9. He was evaluated by our institution for a chief complaint of fever and abdominal pain. He was found to have an enlarged cardiac silhouette (cardiothoracic ratio 77.8%) and extensive pericardial fluid, suggesting the presence of cardiac tamponade due to pericarditis. The patient met the diagnostic criteria for pediatric systemic lupus erythematosus (pSLE) (Japan Ministry of Health, Labour and Welfare, 1986); pericarditis, positive antinuclear antibody, immunological disorder (anti-ds DNA, anti-Sm, anti-U1 RNP), and hypocomplementemia. Other SLE features, such as rash, arthritis, renal involvement, and hematological disorders, were not observed. After an initial methylprednisolone burst, he was treated with 30 mg/day of prednisolone (PSL) and cyclosporine for four weeks, after which the dose of PSL was gradually decreased. The clinical manifestations subsided and antinuclear antibody, anti-dsDNA, and anti-U1 RNP reverted to negative, although hypocomplementemia and antiphospholipid antibodies remained present over the next 20 months of observation. RASopathy is a rare syndrome, and is often complicated by autoimmune disorders such as SLE. In this case, pericarditis was the sole clinical manifestation of pSLE. The clinical features of SLE associated with RASopathy are different from typical childhood-onset SLE.